The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients.

摘要: Bladder cancer (BC) is the 10th most common in UK, with about 10,000 new cases annually. About 75–85% of BC are non-muscle invasive (NMIBC), which associated high recurrence and progression rates (50–60% within 7–10 years). There no routine biomarkers currently available for identifying patients at increased risk developing recurrence. The focus this research study was to evaluate antibody expression their association recurrence. 35 scheduled TURBT were recruited after written informed consent. Ethical approval project granted via IRAS (REC4: 14/WA/0033). Following surgical procedure, tissues preserved 10% buffered formalin processed 24 h FFPE blocks. 7 sections (4 µm each) cut from each block stained CD31, Human epidermal growth factor receptor-2 (HER-2), S100P, Cyclooxygenase-2 (COX-2), VEGFR-3 thrombomodulin CEACAM-1 using immunohistochemistry. Clinical outcome measures (obtained cystoscopy) monitored up 6 months following procedure. significantly CD31 (p < 0.001), HER-2 (p = 0.032), S100P COX-2 (p < 0.001) decreased (p = 0.010) bladder tumours compared normal tissues. also grade (p = 0.003), especially between 1 2 (p = 0.002) 3 (p = 0.004). a significant stage (p < 0.001). Although grade, there expression. Findings present may indicate an alternative approach monitoring management BC. It proposed that by allowing urological surgeons access laboratory markers such as HER-2, Thrombomodulin (biomarker profile), potentially, future, these be used addition to, or combination with, scoring systems predict However, verification validation needed larger cohorts.